» Articles » PMID: 22379174

Recent Advances in the Pathogenesis and Clinical Evaluation of Pulmonary Fibrosis

Overview
Journal Eur Respir Rev
Specialty Pulmonary Medicine
Date 2012 Mar 2
PMID 22379174
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

Interstitial lung diseases (ILDs) are a group of heterogeneous disorders, either idiopathic or associated with injurious or inflammatory causes, in which the major site of damage is the lung interstitium. For a long time, knowledge regarding pathogenesis was trivial and there were difficulties in diagnosing and subsequently treating these diseases. During the past decade, however, there has been an impressive development in the field of ILDs. Idiopathic pulmonary fibrosis, the most common and fatal form of ILD, was initially believed to be due to an inflammatory response to unknown lung injury, whereas nowadays it is believed to be the result of multiple injuries at different sites of the lung followed by aberrant repair. The integration of clinical, radiological and histological data, namely a multidisciplinary team (MDT) approach, has provided grounds for a more accurate diagnosis of ILDs, and helped the identification of different entities and development of different therapeutic approaches. However, because of the complexity of ILDs, even this approach may fail to establish a confident diagnosis. How should the clinician behave in this case and what are the pitfalls of the MDT approach? In addition, since diagnosis is the major predictor of prognosis, are there any other tools available to predict prognosis?

Citing Articles

Identification and validation of targets of swertiamarin on idiopathic pulmonary fibrosis through bioinformatics and molecular docking-based approach.

Chang J, Zou S, Xiao Y, Zhu D BMC Complement Med Ther. 2023; 23(1):352.

PMID: 37798725 PMC: 10557187. DOI: 10.1186/s12906-023-04171-w.


The Pharmacological Efficacy of Baicalin in Inflammatory Diseases.

Wen Y, Wang Y, Zhao C, Zhao B, Wang J Int J Mol Sci. 2023; 24(11).

PMID: 37298268 PMC: 10253382. DOI: 10.3390/ijms24119317.


Perspectives of PDE inhibitor on treating idiopathic pulmonary fibrosis.

Yang X, Xu Z, Hu S, Shen J Front Pharmacol. 2023; 14:1111393.

PMID: 36865908 PMC: 9973527. DOI: 10.3389/fphar.2023.1111393.


Cardiopulmonary exercise testing in interstitial lung diseases and the value of ventilatory efficiency.

Gille T, Laveneziana P Eur Respir Rev. 2021; 30(162).

PMID: 34853093 PMC: 9489146. DOI: 10.1183/16000617.0355-2020.


Airway-centered interstitial fibrosis - an under-recognized subtype of diffuse parenchymal lung diseases.

Silbernagel E, Morresi-Hauf A, Reu S, King B, Gesierich W, Lindner M Sarcoidosis Vasc Diffuse Lung Dis. 2020; 35(3):218-229.

PMID: 32476906 PMC: 7170155. DOI: 10.36141/svdld.v35i3.6432.


References
1.
Yokoyama A, Kondo K, Nakajima M, Matsushima T, Takahashi T, Nishimura M . Prognostic value of circulating KL-6 in idiopathic pulmonary fibrosis. Respirology. 2006; 11(2):164-8. DOI: 10.1111/j.1440-1843.2006.00834.x. View

2.
Kulasekaran P, Scavone C, Rogers D, Arenberg D, Thannickal V, Horowitz J . Endothelin-1 and transforming growth factor-beta1 independently induce fibroblast resistance to apoptosis via AKT activation. Am J Respir Cell Mol Biol. 2009; 41(4):484-93. PMC: 2746991. DOI: 10.1165/rcmb.2008-0447OC. View

3.
Chambers R, Leoni P, Wembridge D, Laurent G . Thrombin is a potent inducer of connective tissue growth factor production via proteolytic activation of protease-activated receptor-1. J Biol Chem. 2000; 275(45):35584-91. DOI: 10.1074/jbc.M003188200. View

4.
Taille C, Grootenboer-Mignot S, Boursier C, Michel L, Debray M, Fagart J . Identification of periplakin as a new target for autoreactivity in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2010; 183(6):759-66. DOI: 10.1164/rccm.201001-0076OC. View

5.
Behr J, Degenkolb B, Maier K, Braun B, Beinert T, Krombach F . Increased oxidation of extracellular glutathione by bronchoalveolar inflammatory cells in diffuse fibrosing alveolitis. Eur Respir J. 1995; 8(8):1286-92. DOI: 10.1183/09031936.95.08081286. View